share_log

HC Wainwright & Co. Maintains Buy on Ensysce Biosciences, Lowers Price Target to $7

Benzinga ·  Sep 25, 2023 06:12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ensysce Biosciences (NASDAQ:ENSC) with a Buy and lowers the price target from $9 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment